Prevalence and determinants of cervicovaginal, oral, and anal HPV infection in a population of transgender and gender diverse people assigned female at birth.

Autor:	McIntosh RD; Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States., Andrus EC; Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States., Walline HM; Department of Otolaryngology, University of Michigan, Ann Arbor, MI, United States., Sandler CB; Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States., Goudsmit CM; Department of Otolaryngology, University of Michigan, Ann Arbor, MI, United States., Moravek MB; Reproductive Endocrinology Clinic, Center for Reproductive Medicine, University of Michigan, Ann Arbor, MI, United States., Stroumsa D; Reproductive Endocrinology Clinic, Center for Reproductive Medicine, University of Michigan, Ann Arbor, MI, United States., Kattari SK; School of Social Work, University of Michigan, Ann Arbor, MI, United States.; Department of Women's and Gender Studies, University of Michigan, Ann Arbor, MI, United States., Brouwer AF; Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States.
Jazyk:	angličtina
Zdroj:	MedRxiv : the preprint server for health sciences [medRxiv] 2023 Aug 16. Date of Electronic Publication: 2023 Aug 16.
DOI:	10.1101/2023.08.15.23294129
Abstrakt:	Introduction: HPV causes oral, cervicovaginal, and anogenital cancer, and cervical cancer screening options include HPV testing of a physician-collected sample. Transgender and gender diverse (TGD) people assigned female at birth (AFAB) face discrimination and stigma in many healthcare settings; are believed to be a lower risk for cervical cancer by many physicians; are less likely to be up to date on preventive health care services such as pelvic health exams; and are more likely to have inadequate results from screening tests. Self-sampling options may increase access and participation in HPV testing and cancer screening. Methods: We recruited 137 TGD individuals AFAB for an observational study, mailing them a kit to self-collect cervicovaginal, oral, and anal samples at home. We tested samples for HPV genotypes 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73 and 90 using a PCR mass array test. Results: 102 participants completed the study. Among those with valid tests, 8.8% were positive for oral HPV, 30.5% were positive for cervicovaginal HPV, and 39.6% were positive for anal HPV. A large fraction of anal (50.0%) and oral (71.4%) infections were concordant with a cervicovaginal infection of the same type. Conclusions: HPV infection in TGD people AFAB may be just as high, if not higher, than in cisgender women. It is essential that we reduce barriers to cancer screening for TGD populations, such as through the development of a clinically approved self-screening HPV test. Competing Interests: Competing interests All authors declare that they have no competing interests.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu